Curaleaf Holdings (CURLF) Other Non-Current Assets (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Other Non-Current Assets of $12.0 million for Q4 2025, little changed year-on-year from $12.0 million in Q4 2024, and little changed on a QoQ basis from $12.0 million in Q4 2024.
Curaleaf Holdings (CURLF) Other Non-Current Assets (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Other Non-Current Assets for 7 consecutive years, with $12.0 million the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $12.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $12.0 million, changed 0.0% from the prior year.
- Other Non-Current Assets steadied at $12.0 million in Q4 2025 per CURLF's latest filing, from $12.0 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for CURLF reached as high as $17.7 billion in Q1 2022 and fell as low as $8.2 million in Q3 2024.
- A 5-year average of $1.2 billion and a median of $17.6 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets tumbled 81.66% — and 2022, when it surged 57395.28%.
- Year by year, Other Non-Current Assets stood at $24.3 million in 2021, then slumped by 36.27% to $15.5 million in 2022, then tumbled by 44.37% to $8.6 million in 2023, then jumped by 39.53% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $12.0 million, $12.0 million, and $8.2 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.00 Mn |
| Dec 31, 2024 | 12.00 Mn |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 9.11 Mn |
| Dec 31, 2023 | 8.60 Mn |
| Sep 30, 2023 | 11.18 Mn |
| Jun 30, 2023 | 46.79 Mn |
| Dec 31, 2022 | 15.46 Mn |
| Sep 30, 2022 | 18.95 Mn |
| Jun 30, 2022 | 17.61 Mn |
| Mar 31, 2022 | 17.67 Bn |
| Dec 31, 2021 | 24.26 Mn |
| Sep 30, 2021 | 22.88 Mn |
| Jun 30, 2021 | 45.21 Mn |
| Mar 31, 2021 | 30.73 Mn |
| Dec 31, 2020 | 132.23 Mn |
| Sep 30, 2020 | 34.34 Mn |
| Dec 31, 2019 | 8.83 Mn |
| Sep 30, 2019 | -20.09 Mn |